Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.

Many early drug research efforts are too reductionist thereby not delivering key parameters such as kinetics and thermodynamics of target-ligand binding. A set of human D-Amino Acid Oxidase (DAAO) inhibitors 1-6 was applied to demonstrate the impact of key biophysical techniques and physicochemical methods in the differentiation of chemical entities that cannot be adequately distinguished on the basis of their normalized potency (ligand efficiency) values. The resulting biophysical and physicochemical data were related to relevant pharmacodynamic and pharmacokinetic properties. Surface Plasmon Resonance data indicated prolonged target-ligand residence times for 5 and 6 as compared to 1-4, based on the observed k(off) values. The Isothermal Titration Calorimetry-derived thermodynamic binding profiles of 1-6 to the DAAO enzyme revealed favorable contributions of both ΔH and ΔS to their ΔG values. Surprisingly, the thermodynamic binding profile of 3 elicited a substantially higher favorable contribution of ΔH to ΔG in comparison with the structurally closely related fused bicyclic acid 4. Molecular dynamics simulations and free energy calculations of 1, 3, and 4 led to novel insights into the thermodynamic properties of the binding process at an atomic level and in the different thermodynamic signatures of 3 and 4. The presented holistic approach is anticipated to facilitate the identification of compounds with best-in-class properties at an early research stage.

[1]  Mark A. Miller,et al.  Why is it so difficult to simulate entropies, free energies, and their differences? , 2001, Accounts of chemical research.

[2]  Thomas J. Raub,et al.  In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.

[3]  Paul J. Harrison,et al.  The neurobiology of D-amino acid oxidase and its involvement in schizophrenia , 2010, Molecular Psychiatry.

[4]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[5]  J. Elguero,et al.  13C NMR chemical shifts of N-unsubstituted- and N-methyl-pyrazole derivatives , 1984 .

[6]  György G Ferenczy,et al.  Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.

[7]  Paul J. Harrison,et al.  d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia , 2007, The European journal of neuroscience.

[8]  J. Uslaner,et al.  The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors , 2010, The open medicinal chemistry journal.

[9]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[10]  G. Holdgate,et al.  Measurements of binding thermodynamics in drug discovery. , 2005, Drug discovery today.

[11]  Walter Huber,et al.  A new strategy for improved secondary screening and lead optimization using high‐resolution SPR characterization of compound–target interactions , 2005, Journal of molecular recognition : JMR.

[12]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[13]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Venkatraman,et al.  The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[15]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[16]  Wei Zheng,et al.  A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase , 2006, Journal of biomolecular screening.

[17]  U. Helena Danielson,et al.  Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. , 2009, Future medicinal chemistry.

[18]  Gerhard Klebe,et al.  Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.

[19]  Michael Williams Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. , 2009, Biochemical pharmacology.

[20]  J. Roder,et al.  The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia , 2010, Neuroscience & Biobehavioral Reviews.

[21]  Sarah L. Huszar,et al.  The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine , 2008, Journal of Pharmacology and Experimental Therapeutics.

[22]  D. E. Clark In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[23]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[24]  K. Muir Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. , 2006, Current opinion in pharmacology.

[25]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[26]  L. Pollegioni,et al.  Characterization of human d‐amino acid oxidase , 2006, FEBS letters.

[27]  Tjelvar S. G. Olsson,et al.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.

[28]  P. Skolnick,et al.  Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.

[29]  E. Freire Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.

[30]  Hugues Dolgos,et al.  Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.

[31]  J. Elguero,et al.  13C NMR of pyrazoles , 1993 .

[32]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[33]  Wilfred F van Gunsteren,et al.  Biomolecular modeling: Goals, problems, perspectives. , 2006, Angewandte Chemie.

[34]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[35]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[36]  Wilfred F. van Gunsteren,et al.  An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase , 2001, J. Comput. Chem..

[37]  K. Hashimoto,et al.  Synthesis and biological evaluation of D-amino acid oxidase inhibitors. , 2008, Journal of medicinal chemistry.

[38]  Wesley Schaal,et al.  Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. , 2002, Journal of medicinal chemistry.

[39]  R. Panizzutti,et al.  A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia , 2007, Schizophrenia Research.

[40]  Paul J. Harrison,et al.  D-Amino acid oxidase activity and expression are increased in schizophrenia , 2008, Molecular Psychiatry.

[41]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[42]  L. Cavarec,et al.  In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties , 2008, European Neuropsychopharmacology.

[43]  M. Mansour,et al.  Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. , 2009, Journal of medicinal chemistry.

[44]  J. Schlitter Estimation of absolute and relative entropies of macromolecules using the covariance matrix , 1993 .

[45]  Gerhard Klebe,et al.  Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.

[46]  F. Monsma,et al.  Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs , 2010, Expert opinion on drug discovery.

[47]  Jörg Huwyler,et al.  In silico prediction of brain and CSF permeation of small molecules using PLS regression models. , 2008, European journal of medicinal chemistry.

[48]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[49]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[50]  Markus Christen,et al.  The GROMOS software for biomolecular simulation: GROMOS05 , 2005, J. Comput. Chem..

[51]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[52]  Herman Wolosker,et al.  d‐Amino acids in the brain: d‐serine in neurotransmission and neurodegeneration , 2008, The FEBS journal.

[53]  Robert A Copeland,et al.  The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety , 2010, Expert opinion on drug discovery.

[54]  Yue-Cune Chang,et al.  D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia , 2006, Biological Psychiatry.

[55]  D. Javitt,et al.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. , 2010, Clinical schizophrenia & related psychoses.

[56]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[57]  D. Swinney The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.

[58]  H. Tsuge,et al.  Crystal structure of human D‐amino acid oxidase: Context‐dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si‐face of the flavin ring , 2006, Protein science : a publication of the Protein Society.

[59]  P. Tonge,et al.  Drug-target residence time: critical information for lead optimization. , 2010, Current opinion in chemical biology.

[60]  J. Elguero,et al.  PACKING MODES IN EIGHT 3-ETHOXYCARBONYLPYRAZOLE DERIVATIVES. INFLUENCE OF THE SUBSTITUENTS ON THE CRYSTAL STRUCTURE AND ANNULAR TAUTOMERISM , 1999 .

[61]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[62]  Daniel C Javitt,et al.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. , 2007, International review of neurobiology.

[63]  F. Ceciliani,et al.  Purification of beef kidney D-aspartate oxidase overexpressed in Escherichia coli and characterization of its redox potentials and oxidative activity towards agonists and antagonists of excitatory amino acid receptors. , 1999, Biochimica et biophysica acta.

[64]  D. Erlanson Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[65]  M. S. Pilone,et al.  D-Amino acid oxidase: new findings , 2000, Cellular and Molecular Life Sciences CMLS.

[66]  G. Tsai New Approaches to Treatment of Schizophrenia by Enhancing N -methyl- D -aspartate Neurotransmission , 2008 .

[67]  Wilfred F. van Gunsteren,et al.  A generalized reaction field method for molecular dynamics simulations , 1995 .

[68]  S. Oliet,et al.  Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine , 2009, Neuroscience.

[69]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[70]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[71]  J. Kirkwood Statistical Mechanics of Fluid Mixtures , 1935 .

[72]  Julen Oyarzabal,et al.  In vivo, in vitro and in silico methods for small molecule transfer across the BBB. , 2009, Journal of pharmaceutical sciences.

[73]  W. V. van Gunsteren,et al.  Estimating entropies from molecular dynamics simulations. , 2004, The Journal of chemical physics.

[74]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[75]  James Andrew McCammon,et al.  Ligand-receptor interactions , 1984, Comput. Chem..

[76]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[77]  C. Parsons,et al.  NMDA receptors as targets for drug action in neuropathic pain. , 2001, European journal of pharmacology.